Ascendis Pharma A/S
ASND- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001612042
In the last 90 days, Ascendis Pharma A/S insiders filed 1 open-market purchase and 2 sales; 315 institutions reported holding it in 13F filings for Q2 2026, worth $17.8B in total; no superinvestor holds it.
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysLast 90 days, $492.7K in total
- 1
- Insider sellsLast 90 days, $872.9K in total
- 2
- 13F holdersQ2 2026, +40 vs. previous quarter
- 315
- 13F valueReported value at the end of Q2 2026
- $17.8B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in EUR.
- Revenue, FY2025
- EUR 720.1M
- +98.0% year over year
- Net income, FY2025
- EUR -228.0M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: EUR 228.0M (31.7% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 3.13M
- Shares sold short
- Change
- −351.6K
- −10.1% vs. previous
- Days to cover
- 4.15
- At average daily volume
Superinvestors holding ASND, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ASND at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Ascendis Pharma A/S insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 (view filing)5:04 PM ET | Sep 8 | 1 day | Bodenhoff MadsSVP & PAO | SSale | −3.00K | $270.19 | −$810.6K | −100.0%0 after | |
| Sep 3, 2026 (view filing)4:09 PM ET | Sep 2 | 1 day | Holtug LarsDirector | SSale | −236 | $264.13 | −$62.3K | −5.6%4.00K after | |
| Aug 18, 2026 (view filing)9:02 PM ET | Aug 14 | 4 days | Bienaime Jean JacquesDirector | PPurchase | +2.00K | $246.33 | +$492.7K | +222.2%2.90K after | 2 lots |
| Jun 2, 2026 (view filing) | Jun 2 | Same day | Smith Scott ThomasEVP & Chief Financial Officer | PPurchase | +100 | $219.00 | +$21.9K | +2.3%4.37K after | |
| Jun 1, 2026 (view filing) | May 29 | 3 days | Bienaime Jean JacquesDirector | PPurchase | +500 | $223.12 | +$111.6K | +125.0%900 after | 3 lots |
| Jun 1, 2026 (view filing) | May 29 | 3 days | Smith Scott ThomasEVP & Chief Financial Officer | PPurchase | +250 | $223.32 | +$55.8K | +6.2%4.27K after | |
| May 27, 2026 (view filing) | May 26 | 1 day | Bienaime Jean JacquesDirector | PPurchase | +400 | $237.81 | +$95.1K | New position400 after | 2 lots |
| May 12, 2026 (view filing) | May 11 | 1 day | Jensen Flemming SteenSee Remarks | SSale | −19.5K | $238.49 | −$4.64M | −100.0%0 after |
Top 10 13F holders, Q2 2026
See all 315 holdersThe largest institutional positions in Ascendis Pharma A/S at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 10,281,496 | $2.74B | 23.83% | 00.0% | Unchanged |
| T. Rowe Price Investment Management, Inc. | 6,754,846 | $1.80B | 1.18% | +592,804+9.6% | Added |
| Avoro Capital Advisors LLC | 5,111,111 | $1.36B | 12.24% | +48,611+1.0% | Added |
| Westfield Capital Management Co LP | 4,798,267 | $1.28B | 4.18% | −15,173−0.3% | Reduced |
| Jupiter Topco LLC | 3,648,772 | $973.4M | 0.40% | +3,648,772 | New |
| FMR LLC | 3,545,575 | $945.7M | 0.04% | −331,026−8.5% | Reduced |
| Artisan Partners Limited Partnership | 2,634,024 | $702.5M | 1.15% | −596,164−18.5% | Reduced |
| BlackRock, Inc. | 2,211,833 | $589.9M | 0.01% | +1,550,779+234.6% | Added |
| Capital International Investors | 1,988,614 | $530.4M | 0.11% | +29,771+1.5% | Added |
| Massachusetts Financial Services Co | 1,875,301 | $500.1M | 0.16% | +14,632+0.8% | Added |
Holders of 5% or more of ASND
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Ascendis Pharma A/S.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13G/A | 10.50%6.51M shares | +0.60 ppfrom 9.90% | Feb 14, 20247 filings | May 7, 2026 | SEC |
| Westfield Capital Management Co LP | 13G/A | 8.48%5.19M shares | −0.70 ppfrom 9.18% | Feb 2, 20235 filings | Feb 11, 2026 | SEC |
| Janus Henderson Group PLC | 13G/A | 6.00%3.72M shares | −1.80 ppfrom 7.80% | Feb 12, 202110 filings | May 15, 2026 | SEC |
| FMR LLC | 13G/A | 5.20%3.43M shares | −1.40 ppfrom 6.60% | Feb 8, 20218 filings | Nov 5, 2026 | SEC |
| Artisan Partners Limited Partnership | 13G/A | 5.20%3.23M shares | – | Feb 10, 20216 filings | Feb 3, 2026 | SEC |